DYNbenzinga

Dyne Therapeutics Announced Clinical Data From Its Ongoing Phase 1/2 ACHIEVE Trial Of DYNE-101 In Myotonic Dystrophy Type 1 And Phase 1/2 DELIVER Trial Of DYNE-251 In Duchenne Muscular Dystrophy

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on May 20, 2024 by benzinga